News | September 30, 2008

GE, Gamma Medica-Ideas Extend Pre-Clinical PET, SPECT Deal

October 1, 2008 — GE Healthcare and Gamma Medica-Ideas (GM-I) have extended their product distribution relationship to include joint development of pre-clinical imaging systems.

Under the new agreement, which takes effect today. GM-I will manufacture all pre-clinical PET, SPECT and CT products sold by GE Healthcare, including the new eXplore CT120 and SpeCZT model lines. The companies will jointly pursue new pre-clinical product developments expected to lead to exciting new products for pre-clinical imaging. GE Healthcare will continue promotion, marketing, sales, and service responsibilities.

“GM-I has a long track record of innovation in imaging technologies and the pre-clinical business including the introduction of the first APD based PET scanner and the Triumph tri-modality system,” said Jim Mitchell, general manager of the pre-clinical business for GE Healthcare. “This agreement is tremendously beneficial to both companies, bringing GM-I’s engineering and manufacturing expertise and GE’s sales, marketing and services acumen together as well as combining cutting edge pre-clinical imaging technologies of GE and GMI.”

“This is a great opportunity to harmonize GM-I and GE Healthcare’s unique and innovative CZT SPECT, APD PET and high throughput CT imaging systems,” said Bradley Patt Ph.D., CEO of GM-I.

For more information: www.gehealthcare.com and www.gm-ideas.com

Related Content

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...